The global viral vaccines market is poised for substantial growth, with projections indicating a market value of $47.01 billion by 2031. This represents a compound annual growth rate (CAGR) of 1.9% from 2024 to 2031, as detailed in the latest report by Meticulous Research®. This growth trajectory is underpinned by several key drivers, including a robust product pipeline, increasing government focus on immunization, and technological advancements in vaccine administration.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920

Market Overview
The viral vaccines market is experiencing a period of significant expansion, driven by a combination of factors including the strong pipeline of vaccine products, heightened governmental emphasis on immunization programs, and advancements in vaccine technology. The growing use of inactivated vaccines in medical procedures and the expansion of biopharmaceutical production capabilities are also contributing to market growth.

Key trends shaping the market include an increasing focus on therapeutic vaccines, the rising use of adjuvants, and the development of highly stable, energy-efficient ultra-low temperature freezers. These advancements are creating new growth opportunities for market players and enhancing the overall landscape of viral vaccination.

Market Segmentation
The viral vaccines market is segmented across various parameters, each offering unique insights into market dynamics:

By Form
The market is segmented into liquid and lyophilized vaccines. In 2024, the liquid vaccines segment is expected to capture the largest market share. Liquid vaccines are favored for their ease of administration, eliminating the need for reconstitution, which reduces the risk of errors and simplifies logistics compared to lyophilized vaccines. This form's advantages include reduced equipment and training requirements, lower contamination risks, and minimized vaccine accessory wastage.

By Vaccine Type
Vaccine types include live-attenuated, inactivated, mRNA, viral vector, subunit & conjugate, toxoid, and combination vaccines. The subunit & conjugate vaccines segment is anticipated to dominate in 2024. This segment's growth is attributed to the absence of live components, precise pathogen targeting, and the ability to elicit strong immune responses with low immunogenicity risks, ensuring long-term immunity.

By Virus Type
The market is categorized by virus types such as adenovirus, retrovirus, plasmid DNA, adeno-associated virus (AAV), lentivirus, and others. The adenovirus segment is projected to hold the largest share in 2024. Adenoviruses are known for their efficient gene delivery, strong immune response, and high scalability, which makes them a preferred choice for vaccine development.

Recent collaborations, such as those announced in January 2024 between ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, Harvard (U.S.), and the International AIDS Vaccine Initiative (IAVI) (U.S.), underscore the growing interest in adenoviral vector-based vaccines. This partnership aims to develop a novel HIV vaccine candidate, utilizing advanced vector engineering and process development to evaluate the vaccine's safety and efficacy.

By Approach
The market is segmented into preventive and therapeutic vaccines. Preventive vaccines are expected to command a larger market share in 2024. This segment's growth is driven by the increasing prevalence of chronic and infectious diseases, rising public awareness of immunization, and the role of vaccines in inducing herd immunity and preventing disease outbreaks.

By Indication
Viral vaccines target various indications including infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is forecasted to hold the largest market share. This is due to the vaccines' role in preventing diseases, reducing morbidity and mortality rates, and enhancing global health security. For instance, the R21/Matrix-M malaria vaccine, developed by Oxford University (U.K.) and the Serum Institute of India Pvt Ltd (India), and recommended by the WHO's Strategic Advisory Group of Experts (SAGE), exemplifies advancements in this segment.

By Application
Applications in the market include antisense therapy, gene therapy, cell therapy, and vaccinology. In 2024, the antisense therapy segment is expected to lead. Antisense vaccines are increasingly adopted due to their ability to induce comprehensive immune responses and their potential to address a wide range of pathogens.

By Packaging
The market is divided into vials and prefilled syringes. The choice of packaging impacts vaccine distribution and administration efficiency.

By Geography
Geographically, the market spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is projected to hold the largest market share in 2024. Factors contributing to this dominance include advanced research infrastructure, the presence of leading pharmaceutical companies, and collaborations between research institutes and industry players. The region's preparedness for emerging pandemics further reinforces its position.

Conversely, the Asia-Pacific region is expected to exhibit the highest CAGR, driven by rapid industrialization, government initiatives, and a growing focus on improving healthcare infrastructure.

Key Players
The viral vaccines market features several prominent players who are driving innovation and growth. Notable companies include:

Pfizer, Inc. (U.S.)
AstraZeneca plc (U.K.)
GlaxoSmithKline plc (U.K.)
Sanofi S.A. (Italy)
CSL Ltd. (Australia)
Mitsubishi Tanabe Pharma Corporation (Japan)
Merck & Co., Inc. (U.S.)
Moderna, Inc. (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
Dynavax Technologies Corporation (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Emergent BioSolutions, Inc. (U.S.)
Bharat Biotech International Limited (BBIL) (India)
Valneva SE (France)

Read Full Report @ https://www.meticulousresearch.com/product/viral-vaccines-market-5920

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research